Progyny Announces Revolving Credit Facility and Improved Q2 2025 Financial Outlook

By Philip Seaworth • Tuesday, July 08 10:15 • Permanent Link

Progyny, Inc. (NASDAQ: PGNY) has provided a business update and announced details for its second quarter 2025 results report. The company has entered into a revolving credit facility, making available up to $200 million in aggregate revolving credit commitments until maturity on July 1, 2030. The undrawn facility is expected to enhance operational and financial flexibility.

The company expects its financial results for the quarterly period ending June 30, 2025, to be slightly better than the guidance ranges provided during its first quarter earnings call. Specifically, second quarter results for revenue, adjusted net income, and adjusted EBITDA are anticipated to be slightly above the previously provided ranges.

Progyny will report its financial results for the quarterly period ended June 30, 2025, after the close of the market on Thursday, August 7, 2025. A conference call will be hosted at 4:45 p.m. Eastern time on the same day, and a press release regarding its financial results will be issued prior to the start of the call.

Interested participants in the United States may access the conference call by dialing 1.866.825.7331, and international participants may access the call by dialing 1.973.413.6106, using the passcode 265484. An audio replay of the call will be available through Thursday, August 14, 2025.

Progyny, Inc. (NASDAQ: PGNY) is a global leader in women's health and family building solutions, trusted by leading employers, health plans, and benefit purchasers. The company's benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists; drives optimal clinical outcomes; and reduces healthcare costs. Following these announcements, the company's shares moved -0.05%, and are now trading at a price of $21.45. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.